Cancer Kidney Disease
Conditions
Interventions
Febuxostat
Sponsors
Basma samir
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Male or female patients -Age ranged from 18 to 75 years old. -Newly diagnosed patients with cancer and with an indication for cisplatin -based chemotherapy. -Patients who scheduled to receive at least four to six cycles of cisplatin. -Patients with no previous renal diseases (including acute nephropathy, acute and chronic renal failure) and taking no kidney -related drugs. -Patients with normal hepatic and renal function (bilirubin =1.2mg/dL, creatinine =1.5 mg/dL)
Exclusion criteria
Exclusion criteria: Hypersensitivity to febuxostat. -Any condition that contraindicates chemotherapy (i.e., pregnancy, lactation). -Acute renal failure or renal surgery within the last 3 months. -Patients with known history or current treatment with nephrotoxic agents. - Subject receiving radiation. -Patients with diabetes mellitus. -Patients with any liver disease methods
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in serum creatinine and creatinine clearance | — |
Secondary
| Measure | Time frame |
|---|---|
| change in glutathione peroxidase, TNF-a. and urinary kidney injury molecule 1. | — |
Countries
Egypt
Contacts
Public ContactNabila Hefzy
Professor of clinical oncology
Outcome results
None listed